Skip to content

Acupoint application in subjects with primary dysmenorrhea: study protocol for a randomized controlled trial

Acupoint application in subjects with primary dysmenorrhea: study protocol for a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008701
Enrollment
Unknown
Registered
2016-06-22
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea

Interventions

Treatment group A (herbal medicine application on acupoints):herbal medicine application on acupoints
Treatment group B (placebo application on acupoints):placebo application on acupoints

Sponsors

Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Nulliparous women aged between 18 and 30 years; 2. Women who meet to the diagnostic criteria of primary dysmenorrhea in the Primary Dysmenorrhea Consensus Guideline; 3. Women who belonged to qi and blood stagnation pattern or cold and dampness stagnation pattern; 4. Women who have normal menstrual cycles (occurring every 28+/-7 days); 5. Women with Visual Analogue Scale (VAS) score of the menstrual pain more than 40 mm during the baseline menstrual period; 6. Women who complete a dysmenorrhea diary during last 3 menstrual cycles; 7. Women who agree to sign informed consent form and volunteered for the research.

Exclusion criteria

Exclusion criteria: 1. Women with secondary dysmenorrhea, such as endometriosis, polycystic ovarian syndrome, uterine myoma, pelvic inflammatory disease, and other gynecological diseases; 2. Women who complicated with any serious contraindication of cardiovascular, liver, kidney, and hematopoietic system disorders; 4. Women with unconsciousness, cannot express subjective symptoms and mental disease; 4. Women with advanced malignant tumor or other serious wasting disease, infection and bleeding; 5. Women who are planning to have a baby; 6. Women who are receiving or received any other treatment of primary dysmenorrhea in past 3 month.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS);

Secondary

MeasureTime frame
Cox Menstrual Symptom Scale (CMSS);

Contacts

Public ContactJie Yang
jenny_yang_jie@126.com+86 13882296714

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 6, 2026